Imidazo[4,5-b]pyridine inhibitors of B-Raf kinase.
Newhouse, B.J., Wenglowsky, S., Grina, J., Laird, E.R., Voegtli, W.C., Ren, L., Ahrendt, K., Buckmelter, A., Gloor, S.L., Klopfenstein, N., Rudolph, J., Wen, Z., Li, X., Feng, B.(2013) Bioorg Med Chem Lett 23: 5896-5899
- PubMed: 24042006 
- DOI: https://doi.org/10.1016/j.bmcl.2013.08.086
- Primary Citation of Related Structures:  
4MBJ - PubMed Abstract: 
This Letter details the synthesis and evaluation of imidazo[4,5-b]pyridines as inhibitors of B-Raf kinase. These compounds bind in a DFG-in, αC-helix out conformation of B-Raf, which is a binding mode associated with significant kinase selectivity. Structure-activity relationship studies involved optimization of the ATP-cleft binding region of these molecules, and led to compound 23, an inhibitor with excellent enzyme/cell potency, and kinase selectivity.
Organizational Affiliation: 
Array BioPharma Inc., 3200 Walnut Street, Boulder, CO 80301, USA. Electronic address: bnewhouse@arraybiopharma.com.